drugset
drugset / Trial / NCT04252586

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT04252586 ↗

Phase 3 Terminated 21 enrolled Jazz Pharmaceuticals GW Pharmaceuticals Ltd · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will be conducted to evaluate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in participants with Rett syndrome.

Timeline

Start
2020-02-28
Primary completion
2021-06-09
Completion
2021-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 100 mg/ml Oral

Indications

Rett syndrome